Teriparatide Injection
Product Images NDC 68001-693

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Teriparatide (NDC 68001-693). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Teriparatide Injection Carton 10-25 (Teriparatide Injection Carton 10 25)

Teriparatide Injection 560 mcg/2.24 mL (250 mcg/mL) subcutaneous injection prefilled pen packaging label. The carton is labeled for single-patient use only and made by BluePoint Laboratories. It includes dosage information of 20 mcg per dose once daily, storage instructions to refrigerate and not freeze, and warnings not to transfer contents to a syringe. The packaging also provides manufacturer details, a toll-free number, and a barcode.*

FDA Label Image

Teriparatide Injection Label 10-25 (Teriparatide Injection Label 10 25)

Label for Teriparatide Injection 560 mcg/2.24 mL (250 mcg/mL) subcutaneous injectable solution. The label indicates the package contains one single-patient-use prefilled pen delivering 28 doses of 20 mcg each. It is manufactured by Amphastar Pharmaceuticals for BluePoint Laboratories and includes storage instructions to refrigerate and not freeze.*

FDA Label Image

Deliverydevice (Teriparatidedeliverydeviceparts)

Illustration of the Teriparatide Injection Delivery Device parts including the black injection button with yellow shaft, red stripe, blue body with medicine cartridge, and blue cap. Additional components shown are the paper tab, needle, small needle protector, and large needle cover. Note that needles are not included with the device.*

FDA Label Image

Figure1 (Teriparatidefigure1)

A line graph comparing the percent of patients with nonvertebral osteoporotic fractures over months since randomization between Teriparatide injection and placebo groups. The x-axis represents months since randomization (0 to 20), and the y-axis shows percent of patients with fractures (0 to 8%). The Teriparatide group is indicated by a dotted line and the placebo group by a solid line, showing a lower fracture rate in the Teriparatide group over time.*

FDA Label Image

Injectorpen (Teriparatideinjectorpen)

Packaging of Teriparatide 250 ug/mL injection by BluePoint Laboratories. The image displays a clear plastic prefilled syringe with a blue and white label and a blue protective cap, intended for subcutaneous use.*

FDA Label Image

Step1 (Teriparatidestep1)

An instructional illustration showing hands holding and disengaging the cap of a pen-style injection device, likely for the Teriparatide 250 mcg/mL subcutaneous injection by BluePoint Laboratories. The image depicts the first step in preparing the injection pen for use by removing the protective cap.*

FDA Label Image

Step2a (Teriparatidestep2a)

An instructional illustration depicting hands removing the cap from a medical injection pen or syringe, likely demonstrating preparation for a subcutaneous injection.*

FDA Label Image

Step2b (Teriparatidestep2b)

An instructional illustration showing hands removing the cap from a Teriparatide injection pen before administration. The image depicts the step of preparing the subcutaneous injection device, with an arrow indicating the direction to pull the cap off.*

FDA Label Image

Step2c (Teriparatidestep2c)

Instructional illustration showing hands removing the protective cap from a teriparatide 250 mcg/mL subcutaneous injection pen by twisting the cap counterclockwise. The image is a step in the preparation for injecting teriparatide, a human prescription drug by BluePoint Laboratories.*

FDA Label Image

Step2d (Teriparatidestep2d)

An instructional illustration showing the removal of a large needle cover from a Teriparatide subcutaneous injection pen. The image highlights hands gripping the needle cover and pulling it off, indicating preparation for injection.*

FDA Label Image

Step3a (Teriparatidestep3a)

Illustration showing hands holding a pen-like injector device for subcutaneous injection. One hand is gripping the injector barrel while the other hand is pulling off a yellow and red protective cap from the injector tip, indicating preparation for injection.*

FDA Label Image

Step3b (Teriparatidestep3b)

Illustration showing hands holding and preparing a pen-style injection device with a focus on a red stripe mark on the device. The red stripe is highlighted with a label indicating its position on the injection pen.*

FDA Label Image

Step3c (Teriparatidestep3c)

An instructional illustration showing a hand removing the small needle protector from a syringe or injection device. The image highlights the step in preparing a Teriparatide subcutaneous injection by handling the needle protector.*

FDA Label Image

Step4a (Teriparatidestep4a)

An instructional illustration showing hands administering a subcutaneous injection with a syringe into the abdominal area. The image depicts correct grip and angle for injection.*

FDA Label Image

Step4b (Teriparatidestep4b)

An instructional illustration showing a person holding a prefilled injection device and preparing to administer a subcutaneous injection. The image includes a counting sequence from 1 to 5, indicating steps or timing during the injection process.*

FDA Label Image

Step5a (Teriparatidestep5a)

An illustration showing a hand holding a small cylindrical vial with a black cap, highlighted by a blue circle. This image likely relates to the Teriparatide injection product, emphasizing handling or packaging detail.*

FDA Label Image

Step5b (Teriparatidestep5b)

An illustration showing a thumb holding a medication vial with a red prohibition symbol over the vial, indicating not to hold or use the vial in that manner.*

FDA Label Image

Step6a (Teriparatidestep6a)

An instructional illustration showing a hand holding a teriparatide injection pen and removing a large needle cover. The image is likely part of usage instructions for the subcutaneous teriparatide injection.*

FDA Label Image

Step6b (Teriparatidestep6b)

An instructional illustration showing a person holding a Teriparatide injection pen device with both hands. The right hand is twisting the cap or a component of the pen in a clockwise direction, as indicated by a red circular arrow around the cap. This image likely demonstrates part of the preparation or usage steps for the Teriparatide subcutaneous injection pen.*

FDA Label Image

Step6c (Teriparatidestep6c)

An instructional illustration showing a user removing a cap from a Teriparatide subcutaneous injection pen before use. The image depicts hands holding the injector pen, highlighting the preparation step prior to administering the injection.*

FDA Label Image

Step6d (Teriparatidestep6d)

An instructional illustration depicting two hands demonstrating how to remove the cap from a syringe. One hand holds the syringe while the other hand pulls the cap away from the syringe tip in a horizontal direction.*

FDA Label Image

Structure (Teriparatidestructure)

Chemical structure diagram of Teriparatide showing the amino acid sequence from Serine at position 1 to Phenylalanine at position 34 in a linear arrangement with each residue labeled.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.